No other Analysts Reports YetSo far, only Mackie has produced a report on TH's KOL on Monday. Now, admittedly, the company did not really make any news in that KOL presentation that would require analysts to do something, but it is still another indicator to me that TH and the capital markets are not on speaking terms right now. Their capital markets strategy needs a big overhaul and the lack of analyst coverage, fewer analysts covering the stock than previously and the very low trading volume are all things that speak to this very sizable problem. If TH hopes to have a good reaction to their cancer data, assuming it is as good as we hope it will be, they need to have complete overhaul of their capital markets strategy as what they have right now clearly is failing to generate any excitement around the stock. Which is unfortunate given that TH actually has much more to offer investors than it has in the past. I know the NASH trial appears stalled and that the cancer data is not out yet but those are two enormous opportunities and it seems reasonable to me to have some investor interest in them right now given the possibility for success, particulalrly in cancer. Hopefully, they can lean into our new board member for advice as to how to get in the capital markets game in a much better way then the failed approach they are utilizing now.